KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Assets (2016 - 2026)

Edwards Lifesciences has reported Assets over the past 17 years, most recently at $13.7 billion for Q4 2025.

  • For Q4 2025, Assets rose 4.92% year-over-year to $13.7 billion; the TTM value through Dec 2025 reached $13.7 billion, up 4.92%, while the annual FY2025 figure was $13.7 billion, 4.92% up from the prior year.
  • Assets for Q4 2025 was $13.7 billion at Edwards Lifesciences, up from $13.3 billion in the prior quarter.
  • Over five years, Assets peaked at $13.7 billion in Q4 2025 and troughed at $7.2 billion in Q1 2021.
  • A 5-year average of $10.1 billion and a median of $9.2 billion in 2023 define the central range for Assets.
  • Biggest five-year swings in Assets: dropped 2.47% in 2022 and later soared 39.43% in 2024.
  • Year by year, Assets stood at $8.5 billion in 2021, then dropped by 2.47% to $8.3 billion in 2022, then rose by 12.91% to $9.4 billion in 2023, then soared by 39.43% to $13.1 billion in 2024, then rose by 4.92% to $13.7 billion in 2025.
  • Business Quant data shows Assets for EW at $13.7 billion in Q4 2025, $13.3 billion in Q3 2025, and $13.5 billion in Q2 2025.